Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149219170> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W3149219170 endingPage "4275" @default.
- W3149219170 startingPage "4263" @default.
- W3149219170 abstract "Colorectal liver metastasis(CLM)is common worldwide.Targeted therapies with monoclonal antibodies have been proven effective in numerous clinical trials,and are now becoming standards for patients with CLM.Thedevelopment and application of anti-epidermal growth factor receptor(anti-EGFR)and anti-vascular endothelial growth factor(anti-VEGF)antibodies represents significant advances in the treatment of this disease.However,new findings continue to emerge casting doubt on the efficacy of this approach.The Kirsten ratsarcoma viral oncogene(KRAS)has been proven to be a crucial predictor of the success of anti-EGFR treatment in CLM.Whereas a recent study summarizedseveral randomized controlled trials,and showed thatpatients with the KRAS G13D mutation significantlybenefited from the addition of cetuximab in terms of progress-free survival(PFS,4.0 mo vs 1.9 mo,HR=0.51,P=0.004)and overall survival(OS,7.6 mo vs5.7 mo,HR=0.50,P=0.005).Some other studiesalso reported that the KRAS G13D mutation might notbe absolutely predictive of non-responsiveness to antiEGFR therapy.At the same time,'new'RAS mutations,including mutations in neuroblastoma RAS viral(vras)oncogene homolog(NRAS)and exons 3 and 4 of KRAS,have been suggested to be predictors of a poor treatment response.This finding was first reported by the update of the PRIME trial.The update showed that for patients with non-mutated KRAS exon 2 but other RAS mutations,panitumumab-fluorouracil,leucovorin,and oxaliplatin(FOLFOX)4 treatment led to inferior PFS(HR=1.28,95%CI:0.79-2.07)and OS(HR=1.29,95%CI:0.79-2.10),which was consistent with the findings in patients with KRAS mutations in exon 2.Then,the update of the PEAK trial and the FIRE-Ⅲtrial also supported this finding,which would reduce candidates for anti-EGFR therapy but enhance the efficacy.In firstline targeted combination therapy,the regimens of cetuximab plus FOLFOX was called into question because of the inferior prognosis in the COIN trial and the NORDIC-Ⅶtrial.Also,bevacizumab plus oxaliplatin-based chemot" @default.
- W3149219170 created "2021-04-13" @default.
- W3149219170 creator A5000169719 @default.
- W3149219170 creator A5025775475 @default.
- W3149219170 creator A5027793194 @default.
- W3149219170 creator A5031574504 @default.
- W3149219170 creator A5043307933 @default.
- W3149219170 creator A5059822028 @default.
- W3149219170 creator A5060073997 @default.
- W3149219170 creator A5062162049 @default.
- W3149219170 creator A5065255680 @default.
- W3149219170 creator A5067464611 @default.
- W3149219170 creator A5068607867 @default.
- W3149219170 creator A5073161777 @default.
- W3149219170 creator A5088784414 @default.
- W3149219170 date "2014-01-01" @default.
- W3149219170 modified "2023-09-27" @default.
- W3149219170 title "Anti-EGFR and anti-VEGF agents:Important targeted therapies of colorectal liver metastases" @default.
- W3149219170 hasPublicationYear "2014" @default.
- W3149219170 type Work @default.
- W3149219170 sameAs 3149219170 @default.
- W3149219170 citedByCount "1" @default.
- W3149219170 countsByYear W31492191702015 @default.
- W3149219170 crossrefType "journal-article" @default.
- W3149219170 hasAuthorship W3149219170A5000169719 @default.
- W3149219170 hasAuthorship W3149219170A5025775475 @default.
- W3149219170 hasAuthorship W3149219170A5027793194 @default.
- W3149219170 hasAuthorship W3149219170A5031574504 @default.
- W3149219170 hasAuthorship W3149219170A5043307933 @default.
- W3149219170 hasAuthorship W3149219170A5059822028 @default.
- W3149219170 hasAuthorship W3149219170A5060073997 @default.
- W3149219170 hasAuthorship W3149219170A5062162049 @default.
- W3149219170 hasAuthorship W3149219170A5065255680 @default.
- W3149219170 hasAuthorship W3149219170A5067464611 @default.
- W3149219170 hasAuthorship W3149219170A5068607867 @default.
- W3149219170 hasAuthorship W3149219170A5073161777 @default.
- W3149219170 hasAuthorship W3149219170A5088784414 @default.
- W3149219170 hasConcept C121608353 @default.
- W3149219170 hasConcept C126322002 @default.
- W3149219170 hasConcept C143998085 @default.
- W3149219170 hasConcept C21790070 @default.
- W3149219170 hasConcept C2776694085 @default.
- W3149219170 hasConcept C2776705615 @default.
- W3149219170 hasConcept C2777802072 @default.
- W3149219170 hasConcept C2778260052 @default.
- W3149219170 hasConcept C2778332735 @default.
- W3149219170 hasConcept C2779998722 @default.
- W3149219170 hasConcept C2780962732 @default.
- W3149219170 hasConcept C2781187634 @default.
- W3149219170 hasConcept C2781230642 @default.
- W3149219170 hasConcept C502942594 @default.
- W3149219170 hasConcept C526805850 @default.
- W3149219170 hasConcept C71924100 @default.
- W3149219170 hasConceptScore W3149219170C121608353 @default.
- W3149219170 hasConceptScore W3149219170C126322002 @default.
- W3149219170 hasConceptScore W3149219170C143998085 @default.
- W3149219170 hasConceptScore W3149219170C21790070 @default.
- W3149219170 hasConceptScore W3149219170C2776694085 @default.
- W3149219170 hasConceptScore W3149219170C2776705615 @default.
- W3149219170 hasConceptScore W3149219170C2777802072 @default.
- W3149219170 hasConceptScore W3149219170C2778260052 @default.
- W3149219170 hasConceptScore W3149219170C2778332735 @default.
- W3149219170 hasConceptScore W3149219170C2779998722 @default.
- W3149219170 hasConceptScore W3149219170C2780962732 @default.
- W3149219170 hasConceptScore W3149219170C2781187634 @default.
- W3149219170 hasConceptScore W3149219170C2781230642 @default.
- W3149219170 hasConceptScore W3149219170C502942594 @default.
- W3149219170 hasConceptScore W3149219170C526805850 @default.
- W3149219170 hasConceptScore W3149219170C71924100 @default.
- W3149219170 hasIssue "15" @default.
- W3149219170 hasLocation W31492191701 @default.
- W3149219170 hasOpenAccess W3149219170 @default.
- W3149219170 hasPrimaryLocation W31492191701 @default.
- W3149219170 hasRelatedWork W1664223940 @default.
- W3149219170 hasRelatedWork W1921471033 @default.
- W3149219170 hasRelatedWork W1990237162 @default.
- W3149219170 hasRelatedWork W1999295171 @default.
- W3149219170 hasRelatedWork W2057822920 @default.
- W3149219170 hasRelatedWork W2128100876 @default.
- W3149219170 hasRelatedWork W2129772273 @default.
- W3149219170 hasRelatedWork W2321720825 @default.
- W3149219170 hasRelatedWork W2331754067 @default.
- W3149219170 hasRelatedWork W2339181566 @default.
- W3149219170 hasRelatedWork W2414357396 @default.
- W3149219170 hasRelatedWork W2585615416 @default.
- W3149219170 hasRelatedWork W2589978293 @default.
- W3149219170 hasRelatedWork W2786983351 @default.
- W3149219170 hasRelatedWork W2850981198 @default.
- W3149219170 hasRelatedWork W2948146283 @default.
- W3149219170 hasRelatedWork W317545 @default.
- W3149219170 hasRelatedWork W2050497546 @default.
- W3149219170 hasRelatedWork W2518800021 @default.
- W3149219170 hasRelatedWork W3150631730 @default.
- W3149219170 isParatext "false" @default.
- W3149219170 isRetracted "false" @default.
- W3149219170 magId "3149219170" @default.
- W3149219170 workType "article" @default.